Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
- Conditions
- Interventions
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 841
- Registration Number
- NCT02980133
- Locations
- π·πΊ
Teva Investigational Site 50440, Tomsk, Russian Federation
π¬πͺTeva Investigational Site 81044, Tbilisi, Georgia
π¬πͺTeva Investigational Site 81040, Tbilisi, Georgia
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 397
- Registration Number
- NCT02969408
- Locations
- πΊπΈ
Teva Investigational Site 13954, Los Angeles, California, United States
πΊπΈTeva Investigational Site 13930, Houston, Texas, United States
πΊπΈTeva Investigational Site 13942, Miami, Florida, United States
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT02964338
- Locations
- πΊπΈ
Teva Investigational Site 13813, Englewood, Colorado, United States
πΊπΈTeva Investigational Site 13820, Princeton, New Jersey, United States
πΊπΈTeva Investigational Site 13824, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT02945046
- Locations
- πΊπΈ
Teva Investigational Site 13834, Phoenix, Arizona, United States
πΊπΈTeva Investigational Site 13819, Canoga Park, California, United States
πΊπΈTeva Investigational Site 13811, Santa Monica, California, United States
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02937168
- Locations
- πΊπΈ
Teva Investigational Site 13808, New Brunswick, New Jersey, United States
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02817464
- Locations
- πΊπΈ
Teva Investigational Site 001, Philadelphia, Pennsylvania, United States
πΊπΈTeva Investigational Site 002, Norfolk, Virginia, United States
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT02769091
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02680561
- Locations
- πΊπΈ
Teva Investigational Site 13679, Huntington Beach, California, United States
πΊπΈTeva Investigational Site 13678, Raleigh, North Carolina, United States
πΊπΈTeva Investigational Site 13677, San Antonio, Texas, United States
To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT02673567
- Locations
- πΊπΈ
Teva Investigational Site 13529, Glendale, California, United States
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1890
- Registration Number
- NCT02638103
- Locations
- π΅π±
Teva Investigational Site 53366, Lublin, Poland
π΅π±Teva Investigational Site 53365, Poznan, Poland
π―π΅Teva Investigational Site 84061, Sendai-shi, Japan